Valar Labs, a Palo Alto, CA-based developer of computational histology AI (CHAI) tests for predicting response to cancer therapies, raised $22M in Series A funding.
The round was led by DCVC and Andreessen Horowitz (a16z) Bio + Health with participation from Pear VC. Vineeta Agarwala, MD, PhD, General Partner at a16z Bio + Health, and James Hardiman, General Partner at DCVC, will be joining the Board of Directors.
The company intends to use the funds to expand operations and its R&D efforts.
Led by Damir Vrabac (COO), Anirudh Joshi (CEO) & Viswesh Krishna (CTO), Valar Labs is a precision medicine company developing computational histology AI tests for predicting response to cancer therapies. It aims to provide every patient and physician the ability to select the best treatment based on the patient’s tumor biology. Its bladder cancer test, Vesta, predicts which patients are unlikely to benefit from BCG therapy and provides detailed risk stratification for recurrence and progression.
The company is clinically available through its CLIA-certified laboratory in Houston, Texas and can be ordered online.
FinSMEs
31/05/2024